Sulforaphane Inhibits Invasion via Activating ERK1/2 Signaling in Human Glioblastoma U87MG and U373MG Cells

Chunliu Li¹,³, Yan Zhou², Xiaohui Peng², Lianlian Du¹,³, Hua Tian², Gaoxiang Yang², Jing Niu², Wei Wu¹,²,³*

Introduction

Glioblastoma is one of the most common and fatal tumors [1]. It is composed of poorly differentiated neoplastic astrocytes with highly invasive potential. The poor prognosis of glioblastoma primarily results from the severe invasiveness. The commonly used strategies for treatment include surgery, radiation, and chemotherapy. Chemotherapy has been shown to modestly increase survival in patients who failed in surgery and radiotherapy [2]. Implantation of carmustine polymer into the resection cavity before radiotherapy has been confirmed to improve the median survival compared with radiotherapy alone [3]. The first line drug for chemotherapy is the alkylating agent temozolomide (TMZ). Unfortunately, glioblastoma cells often generated resistance to chemotherapy is the alkylating agent temozolomide (TMZ). Hence, the key we study is to find effective therapies to repress migration and invasion. Sulforaphane (SFN) was demonstrated to inhibit cell growth in a variety of tumors. Here, we will further investigate whether SFN inhibits migration and invasion and find the possible mechanisms in human glioblastoma U87MG and U373MG cells.

Methods: First, the optimal time and dose of SFN for migration and invasion study were determined via cell viability and cell morphological assay. Further, scratch assay and transwell invasion assay were employed to investigate the effect of SFN on migration and invasion. Meanwhile, Western blots were used to detect the molecular linkage among invasion related proteins phosphorylated ERK1/2, matrix metalloproteinase-2 (MMP-2) and CD44v6. Furthermore, Gelatin zymography was performed to detect the inhibition of MMP-2 activation. In addition, ERK1/2 blocker PD98059 (25 μM) was integrated to find the link between activated ERK1/2 and invasion, MMP-2 and CD44v6.

Results: The results showed that SFN (20 μM) remarkably reduced the formation of cell pseudopodia, indicating that SFN might inhibit cell motility. As expected, scratch assay and transwell invasion assay showed that SFN inhibited glioblastoma cell migration and invasion. Western blot and Gelatin zymography showed that SFN phosphorylated ERK1/2 in a sustained way, which contributed to the downregulated MMP-2 expression and activity, and the upregulated CD44v6 expression. These molecular interactions resulted in the inhibition of cell invasion.

Conclusions: SFN inhibited migration and invasion processes. Furthermore, SFN inhibited invasion via activating ERK1/2 in a sustained way. The accumulated ERK1/2 activation downregulated MMP-2 expression and decreased its activity and upregulated CD44v6. SFN might be a potential therapeutic agent by activating ERK1/2 signaling against human glioblastoma.
Sulforaphane Inhibits Migration and Invasion

Reagents

D.L-Sulforaphane (SFN) was acquired from Sigma (St Louis, MO, USA). Dimethyl sulfoxide (DMSO) was bought from AppliChem GmbH (Otoweg4, D-64291 Darmstadt, Germany). MTS assay kit was purchased from Promega (Madison, USA). DMEM/HIGH glucose culture medium was purchased from Hyclone (Logan, Utah, USA). Fetal bovine serum (FBS) and penicillin-streptomycin were acquired from Invitrogen (Carlsbad, CA, USA). Transwell plates for invasion assay were purchased from BD Biosciences (Bedford, MA, USA). The antibodies, anti-ERK1/2, anti-phospho-ERK1/2 and anti-MMP-2 were purchased from Cell Signaling Technology, Inc (Shanghai, China). Anti-CD44v6 was purchased from Abcam (Hong Kong).

Cell Culture

Human glioblastoma cell line (U87MG) was purchased from the Cell Resource Center, Peking Union Medical College (CRC/ PUMC). U373MG was purchased from American Type Culture Collection (ATCC, USA). The two cell lines are commonly used as models of glioblastoma and present a spectrum of different genetic lesions [36]. The cells were maintained in DMEM/HIGH glucose culture medium supplemented with 10% FBS, 100 U/ml penicillin and 100 U/ml streptomycin in a standard humidified incubator containing 5% CO2 at 37°C. The medium was refreshed every 2 days. Cells were trypsinized by trypsin-EDTA. The cells in the logarithmic growth phase were used to conduct the experiments described as follows. All experiments were done in triplicate.

MTS Assay

SFN was dissolved in DMSO, stored at −20°C and diluted to the desired concentration immediately before the experiments. The final amount of the DMSO did not exceed 0.1% v/v. The cell viability was determined using the CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS Assay) kit according to the manufacturer’s instructions. The cells were plated in 96-well plates at 4–6×104 cells per well overnight. Then, the FBS-free media containing various doses of SFN were used. After 24 h, 20 μl of the pre-warmed MTS reagent was added to each of the wells and the medium was refreshed every 2 days. At 3–5 vision fields were chosen to see the percentage of the measured absorbance of the control group treated with 0.1% DMSO v/v. Each assay was performed in triplicate, and the results were expressed as the mean (± SD).

Morphological Observation

U87MG and U373MG cells were grown to 70%−80% confluence in 6-well culture plates. Then various doses of SFN were added to the media. Morphological changes were documented with a phase-contrast microscope at ×100 magnification (Leica, Germany) connected to a digital camera (Olympus, Japan) at different time points. At 3–5 vision fields were chosen to see the cell morphology.

Scratch Assay

The glioma cells were grown to confluence in 6-well culture plates. Then they were scratched with 200 μl pipette tips. After the suspended cells were washed for three times, the wounded monolayers were cultured in FBS-free media with various doses of SFN for 24 h. Closure of the wounded areas was observed.
under a phase-contrast microscope at ×40 magnification (Leica, Germany) and quantified with the NIH Image J image processing program. The wound area was photographed at the indicated time intervals (T = 0, 24 h) with Olympus DP71 camera (Japan). These experiments were performed in triplicate.

Invasion Assay

Cell invasion was performed using BD BioCoat Matrigel™ invasion chambers (BD Biosciences, USA) pre-coated with BD Matrigel matrix. The 24-well artificial basement membrane inserts had 8 μm pores allowing these single cells to invade. The assay insert plates were prepared by rehydrating the BD Matrigel with 300 μl pre-warmed serum-free medium at room temperature for 30 min. The remaining medium was carefully removed. The number of 1×10^5 of control cells, SFN (optimal dose acquired by the MTS assay and morphological observation) treated cells and SFN combined with PD98059 (25 μM) treated cells suspended in 300 μl DMEM medium without FBS were added separately onto the apical chambers. A volume of 500 μl DMEM medium with 10% FBS was added to the basal chambers. Assay plates were incubated for 24 h incubation in 37°C, 5% CO2 incubator. The non-invading cells on the top chamber were removed gently with a cotton swab. The invaded cells on the bottom of the chamber were fixed with 100% methanol for 20 min at −20°C, and then stained with 0.5% crystal violet solution (made in 25% methanol) at room temperature for 20 min. After the crystal violet solution was moved away, the cells were rinsed with distilled water until excess dye was removed. Twelve vision fields were selected randomly per well under a microscope and the number of cells that penetrated the membrane was counted. Images were acquired with a Leica DMI2R microscope at ×40 magnification.

Immunoblotting

U87MG and U373MG cells were collected and lysed with lysis buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 0.1% SDS, 1% sodium deoxycholate and protease inhibitors, Thermo Scientific, USA). Cell lysate was centrifuged at 18,000xg for 20 min. Total protein concentrations were tested by BCA Protein Assay Kit (Invitrogen, Carlsbad, CA, USA). Equal amounts of total protein were loaded on 10% SDS-PAGE gels and run for required time depending on the molecular weight, then transferred to nitrocellulose membranes via semi-dry transfer. The membranes were blocked in 1.5% BSA in TBS-Tween 20 (TBS-T) buffer for 1 h at room temperature with gentle shaking, incubated at 4°C overnight with primary antibodies against ERK1/2, phospho-ERK1/2, MMP-2, CD44v6, and α-tubulin. After washing with TBS-T for 3x10 minutes each, the membranes were probed with the fluorescence-labeled secondary antibody (LI-COR Bioscience, Lincoln, NE, USA) for 1 h at room temperature. After three washes, the membranes were scanned in both the 700 and 800 channels using the Odyssey Infrared Imaging System (LI-COR Bioscience). The band for α-tubulin was used for equal loading and normalization. Antibodies were diluted appropriately following the protocols provided by the vendors.

Gelatin Zymography

MMP-2 activity was measured using gelatin gel zymography. After we changed the 10% FBS DMEM medium into serum-free medium, the ERK1/2 blocker PD98059 (25 μM) or SFN (appropriate dose) was applied to treat cells, and cultured for 24 h. Medium with secreted MMP-2 protein was collected from an equal number of cells and was centrifuged at 2000 rpm for 10 min to remove cellular debris. Then we collected the supernatant and mixed it with equal amount of sample buffer for loading in the gel. The equal volumes of medium were run on 10% SDS-polyacrylamide gel containing 1 mg/ml gelatin as a protease substrate. The gel was washed in 2.5% Triton X-100 solution at room temperature with gentle agitation 2×30 minutes each, followed by incubation at 37°C for 42 h in the buffer (50 mM Tris-HCl, pH 7.5, 0.2 M NaCl, 5 mM CaCl₂, 2H₂O, and 0.02% Brij-35, pH 7.6). After incubation, the gel was stained for 40 min with staining solution (0.5% Coomassie Brilliant Blue, 25% isopropanol, and 10% acetic acid). Then we destained the stained gel with an appropriate Coomassie R-250 destaining solution (50% methanol, 10% acetic acid). At last, we could see dark blue background against unstained regions of protease-digested gelatin.

Statistical Analysis

Data are expressed as means ± SD. Differences were evaluated using one-way ANOVA for multiple comparisons and t tests for 2-group comparisons. All statistical analyses were performed using SPSS 18.0 software package. Every experiment was repeated at least three times. P<0.05 was considered statistically significant.

Results

SFN Inhibited Cell Viability in a Dose-dependent Manner

SFN inhibited cell growth in a variety of tumors, thus we detected if SFN inhibited the viability of U87MG and U373MG cells. In order to obtain the dose-response curve, we treated tumor cells with the increasing doses of SFN (0, 10, 20, 30, 40, 50, 60, 70, 80, and 90 μM) for 24 h. The treatment time 24 h was determined by our previous study, which the treatment duration might cause a sustained ERK1/2 activation [27,28]. The viability of the SFN-treated cells was then measured by MTS assay. The results showed that the cell viability was decreased after treated by SFN (more than 20 μM) for 24 h in a dose-dependent manner (Figure 1). Meanwhile, we found that SFN did not decrease cell viability significantly at the dose of 20 μM. Therefore, we will use 20 μM as the optimal dose of SFN for our further studies, especially for migration and invasion test.

SFN Changed Cell Morphology in Dose- and Time-dependent Manners

Morphological observation showed that SFN-treated cells exhibited smooth surfaces with obvious reduction of pseudopodia (Figure 2A, Figure 2B). Moreover, in our experiments, cellular morphology changed in both dose- and time-dependent manners. Thus, we proposed that SFN might inhibit cell migration and invasion in U87MG and U373MG cells. Considering that there was no significant death in U075MG and U373MG cells treated with 20 μM SFN for 24 h, and simultaneously obvious morphological changes were observed, we chose 20 μM, 24 h as the optimal dose and time for further study.

SFN Inhibited Migration in U87MG and U373MG Cells

We next performed a commonly used wound healing assay - scratch assay, to determine the influence of SFN on cell migration over a period of 24 h. Figure 3 shows that the cells infiltrated the gap after 24 h in the control group. SFN significantly decreased cell migration versus the control group in U075MG and U373MG cells.

SFN Inhibited Invasion via a Dose-dependent Manner

To determine whether SFN weakens the cell invasive potential, Transwell matrigel invasion assays were conducted. The cells
Figure 1. SFN inhibited cell viability. An in vitro study was initiated by treating U87MG and U373MG cells with increasing doses of SFN (0, 10, 20, 30, 40, 50, 60, 70, 80 and 90 μM) for 24 h. The viability of the SFN-treated cells was measured using the MTS assay. Results were expressed as a percentage of control, which was considered as 100%. Data were reported as mean ± SD and at least three separate experiments were performed. doi:10.1371/journal.pone.0090520.g001

Figure 2. SFN changed cell morphology. (A) Cellular morphological changes in U87MG and U373MG cell lines were done in a dose-dependent manner after treated with SFN for 24 h when observed by a Leica DMIRB Microscope at ×100 magnification. (B) Cellular morphological changes in U87MG and U373MG cell lines were done in a time-dependent manner after treated with 20 μM SFN when observed by a Leica DMIRB Microscope at ×100 magnification. doi:10.1371/journal.pone.0090520.g002
Figure 3. SFN inhibited migration in U87MG and U373MG cell lines. Confluent U87MG and U373MG cells were scratched and incubated at different concentrations of SFN (μM). The area covered by migrating cells was recorded by phase-contrast microscopy connected to a digital camera at time 0 and 24 h. The wound closure area was calculated by measuring the diminution of the wound bed surface upon time using Image J software. Representative pictures of three independent experiments were shown. *, indicates $P<0.05$ versus no SFN group.

doi:10.1371/journal.pone.0090520.g003
invading through the matrigel were counted. The results showed that the cell numbers in the following groups (10, 20, 30 μM) treated with SFN for 24 h were significantly decreased versus control cells (0 μM) following a dose-dependent manner (Figure 4). Clearly, SFN attenuated the cell invasive ability significantly.

SFN Activated ERK1/2 in Dose- and Time-dependent Manners

Since we have found that SFN inhibited cell migration and invasion in U87MG and U373MG cells, we tried to characterize the involved molecular mechanisms. SFN was added to the medium at the doses of 0, 10, 20 and 30 μM for 24 h. Western blot showed that SFN increased ERK1/2 phosphorylation in a dose-dependent manner. Phosphorylation of ERK1/2 was

Figure 4. SFN inhibited invasion in a dose-dependent manner in U87MG and U373MG cell lines. Approximately 1×10⁵ cells were seeded in the 24-well plate with cell culture inserts, the cells were treated with different concentrations of SFN (μM) for 24 h to test invasion. Assays were performed as described in Materials and Methods. The results showed that SFN inhibited significantly cell invasion in a dose-dependent manner. *, indicates P<0.05 versus no SFN group. Data were shown as means ± SD from three independent experiments. doi:10.1371/journal.pone.0090520.g004
increased significantly once the cells were treated with 20 μM SFN (Figure 5A). Furthermore, once the cells were treated with 20 μM SFN at different time points (0, 3, 6, 12, 24, 48 h), the results showed that ERK1/2 phosphorylation was increased to peak when the cells were treated for 24 h (Figure 5B). These results indicated that SFN activated ERK1/2 in a time-dependent manner.

SFN Inhibited Invasion via Sustained Activation of ERK1/2

Three different groups, including the control group (DMSO only), the SFN (20 μM) treatment, the SFN (20 μM) plus PD98059 (25 μM) treatment were made. After the cells were treated with PD98059 (25 μM), a specific ERK1/2 blocker, ERK1/2 phosphorylation was significantly diminished (Figure 6A). When the cells were treated with SFN (20 μM) alone, the cell invasion ability was decreased versus the control group (Figure 6B). After the cells were pretreated with PD98059 for 30 min, then treated with SFN for 24 h, the cell invasion ability in this group was increased significantly in contrast with the SFN only group. These results indicated that SFN inhibited invasion via sustained ERK1/2 activation in U87MG and U373MG cells.

SFN Inhibited MMP-2 Expression and Activity via Sustained Activation of ERK1/2

To verify the molecular signaling for SFN-triggered invasion inhibition, we analyzed downstream MMP-2 expression. Western blot showed that SFN downregulated MMP-2 expression, and the level of MMP-2 expression was decreased to 0.48±0.09SD.
(U87MG) and 0.49±0.10SD (U373MG) when the cells were treated with 20 μM SFN for 24 h (control was set as 1) (Figure 7A). To determine whether decreased MMP-2 resulted from sustained phosphorylation of ERK1/2, the cells were treated with PD98059 (25 μM) combined with SFN (20 μM). Treatment with PD98059 and SFN dramatically reduced the downregulation of MMP-2 expression versus SFN-only treatment (Figure 7A). The results indicated that SFN downregulated MMP-2 expression via activating ERK1/2 in a sustained way. In addition, Gelatin zymography assay showed that MMP-2 activity was reduced significantly by SFN (20 μM); meanwhile, SFN (20 μM) downregulated MMP-2 activity via activating ERK1/2 in a sustained manner (Figure 7B).

**Figure 6. SFN Inhibited invasion via sustained activation of ERK1/2.** (A) The U87MG and U373MG cells were respectively treated with SFN (20 μM) without or with PD98059 (25 μM) for 24 h, western blot showed that SFN activated ERK1/2 significantly. PD98059 decreased ERK1/2 phosphorylation. *, indicates P<0.05 versus the control group. Data were shown as means ± SD from three separate tests. (B) We seeded 1×10⁵ cells in a 24-well plate with cell inserts, the cells were added with SFN (20 μM) without or with PD98059 (25 μM) for 24 h to detect cell invasion. Results showed that SFN inhibited cell invasion significantly versus control. SFN plus PD98059 reduced cell invasion inhibition compared with SFN-only. All procedures were performed as described in Methods. *, indicates P<0.05 versus control, # indicates P<0.05 versus SFN-only group. Data were shown as means ± SD from three separate tests. doi:10.1371/journal.pone.0090520.g006

SFN Upregulated CD44v6 via Activating ERK1/2 in a Sustained Way

Western blot showed that SFN (20 μM) upregulated CD44v6, the level of CD44v6 expression was increased to 3.12±0.51SD (U87MG) and 2.51±0.40SD (U373MG) when the cells were treated with 20 μM SFN (control was set as 1) for 24 h (Figure 8). Interestingly, PD98059 (25 μM) significantly reduced the upregulation of CD44v6 versus SFN-only group (Figure 8). These indicated that SFN upregulated CD44v6 via sustained activation of ERK1/2 in the U87MG and U373MG cells.
Discussion

Glioblastoma has highly invasive and fatal features. Tumor cells aggressively invade the surrounding tissue through infiltrating the brain parenchyma, resulting in the failure to clean up the tumor tissues by surgery and the recurrence of glioblastoma after surgery and radiotherapy. The sufferers have bad outcome with a median survival of only 15 months after multiple therapies. Hence there is an urgent need to develop a novel therapy to resist the tumor progress. Chemotherapy is a common strategy to treat glioblastoma in addition to surgery, radiotherapy and gene therapy. The first line agents, such as TMZ, have some defects in tumor resistance and cell toxicity. It is essential to find novel anti-tumor agent. SFN, as a food component, has no cell toxicity and tumor resistance, but has powerful anti-tumor properties. Studies demonstrated the SFN induced apoptosis in both T98G and U87MG glioblastoma cells through the activation of multiple molecular mechanisms [37]. In various tumor cells, SFN regulates many tumor-related events, including cell death, cell cycle and angiogenesis, but SFN-modulated tumor migration or invasion was only reported in some cancers [9,10,11,12].

Here we determined that SFN inhibited tumor migration and invasion. Moreover, we found that SFN inhibited invasion via sustained activation of ERK1/2 and regulation of downstream invasion-related markers, MMP-2 and CD44v6. These results, on one hand, will provide supportive evidence for clinical use of SFN, on the other hand, will be of a great help to find more invasion mechanisms. Here we first demonstrated that SFN has anti-invasion potential via the specific signaling pathways in human glioblastoma U87MG and U373MG cells. ERK1/2 signaling pathway is believed to play an important role in cancer chemotherapy due to its involvement in tumor cell proliferation, induced S-phase arrest, apoptotic cell death and differentiation. Our previous results showed that transient ERK1/2 activation had positive correlation to the expression and activity

Figure 7. SFN decreased MMP-2 expression and activity in U87MG and U373MG cells. (A) SFN decreased MMP-2 expression via activated ERK1/2. We treated the cells with SFN (20 μM) without or with PD98059 (25 μM) for 24 h. Western blot showed that SFN significantly downregulated MMP-2 expression. SFN plus PD98059 reduced the downregulation of MMP-2 expression. The results indicated that SFN regulated MMP-2 expression via ERK1/2 activation. *, indicates P<0.05 versus control. #, indicates P<0.05 versus the SFN group. Data were shown as means ± SD from three separate tests. (B) SFN decreased MMP-2 activity via activated ERK1/2. We collected the conditioned medium from the above treatment for gelatin zymography assay as the methods. The results showed that SFN significantly decreased MMP-2 activity. SFN plus PD98059 significantly reduced MMP-2 activity inhibition versus the SFN-only. *, indicates P<0.05 versus control. #, indicates P<0.05 versus the SFN-only group. Data were shown as means ± SD from three separate tests.

doi:10.1371/journal.pone.0090520.g007
activation. *, indicates medium, CD44v6 expression was reduced significantly versus SFN-only group. That indicated SFN regulated CD44v6 expression via sustained ERK1/2
PD98059 (25 m) for 24 h. Western blot showed that SFN significantly upregulated CD44v6 expression. After PD98059 and SFN were added into the
Figure 8. SFN upregulated CD44v6 expression in U87MG and U373MG cells. We treated the cells with SFN (20 μM) without or with
of downstream invasion-related protein MMP-2 in human glioblastoma U87MG cells [27,28]. Studies showed that SFN caused a significant elevation in the phosphorylation of ERK1/2
invasion inhibition. To our knowledge, no study proved that
degradation of the ECM and basement membrane, as well as
detonated the expression and activity of MMP-2 resulting in the
verify the hypothesis. Sustained activation of ERK1/2 further
activated ERK1/2 accumulated. Further study is required to
phosphatases, which dephosphorylate ERK1/2 and impel them
2 in the nucleus is determined, at least in part, by nuclear
pathway. The results showed that SFN inhibited invasion in U87MG and U373MG glioma cells via sustained ERK1/2 activation. The duration of ERK1/2 phos-
phosphatases to prevent the dephosphorylation of ERK1/2, and then
back to the cytoplasm [39]. Maybe SFN can induce phosphatases
inhibitors to prevent the dephosphorylation of ERK1/2, and then the
phospho-ERK1/2 gather in the nucleus, in other words, the
regulated CD44v6 via sustained ERK1/2 activation, we do not
invasion inhibition yet.
changes in cell shape and plasticity in cytoskeletal dynamics are
mechanisms of SFN regulation, and provide a potential way to
is the effective agent we desired.
Sulforaphane Inhibits Migration and Invasion
Downstream invasion-related protein MMP-2 in human glioblastoma U87MG cells [27,28]. Studies showed that SFN caused a significant elevation in the phosphorylation of ERK1/2 [39]. Thus, we supposed that SFN triggered the ERK1/2 signaling pathway to regulate glioblastoma invasion. In our study, we detected the expression and activity of MMP-2 with the treatment of SFN, and used ERK1/2 inhibitor PD98059 to verify the ERK1/2 signaling pathway. The results showed that SFN inhibited invasion in U87MG and U373MG glioma cells via sustained ERK1/2 activation. The duration of ERK1/2 phosphorylation, as well as the duration of the accumulation of ERK1/2 in the nucleus is determined, at least in part, by nuclear phosphatases, which dephosphorylate ERK1/2 and impel them back to the cytoplasm [39]. Maybe SFN can induce phosphatases inhibitors to prevent the dephosphorylation of ERK1/2, and then the phospho-ERK1/2 gather in the nucleus, in other words, the activated ERK1/2 accumulated. Further study is required to verify the hypothesis. Sustained activation of ERK1/2 further decreased the expression and activity of MMP-2 resulting in the degradation of the ECM and basement membrane, as well as invasion inhibition. To our knowledge, no study proved that sustained activation of ERK1/2 led to invasion inhibition so far.

Previous studies demonstrated that ERK1/2 signaling regulated a number of transcription factors, such as activator protein-1 (AP-1) and nuclear factor-κB (NF-κB) [40]. And other studies showed that AP-1 and NF-κB acted independently or coordinately to regulate many genes involved in the regulation of MMP-2 and CD44v6 expression [41,42]. Our results are consistent with the studies. Moreover, our finding enriches the ERK1/2 signaling pathway.

Changes in cell shape and plasticity in cytoskeletal dynamics are critically involved in cell adhesion, migration, invasion and the whole process of metastasis [43,44]. SFN reduced the formation of pseudopodia and made morphological changes in U87MG and U373MG cells. Maybe that is one of the reasons why SFN inhibited cell migration and invasion in U87MG and U373MG cells. Studies showed that CD44 was related to the pseudopodia formation [45,46], and CD44 participated in many important cellular processes, including adhesion and motility [47]. CD44v6 is an important member of the cell adhesion molecule CD44 family, and plays a crucial role in tumor invasion [48]. Little cell surface expression of CD44v6 was observed in samples of melanoma, neuroblastoma, glioma, cutaneous lymphomas and prostate cancers [46,49]. Studies showed that over-expression of CD44v6 in a rat prostate cancer line decreased metastasis, and decreased expression of CD44v6 could be a predictor of poor prognosis in clinically localized prostate cancer [50]. These studies are consistent with our results that SFN upregulated CD44v6 and inhibited migration and invasion in U87MG and U373MG cells. Therefore, CD44v6 is an important target molecule of SFN in glioblastoma cells migration and invasion progress. Although SFN regulated CD44v6 via sustained ERK1/2 activation, we do not know how CD44v6 works for the migration and invasion inhibition yet.

Absorption and bioavailability are important factors when a compound is to be administered to humans. SFN could achieve high absolute bioavailability even at low dietary doses in rats [51]. In addition, studies reported that normal cells are more resistant to apoptosis induction by SFN than cancer cells [52,53]. In other words, normal cells are less prone to the toxicity of SFN. This might imply that we can find an optimal dose of SFN to inhibit glioblastoma cells in vivo but safe for normal cells.

Clinically, we have to consider the fact that cancer patients already frequently harbor disseminated tumor cells in their blood, distant organs, and bone marrow when diagnosed [43]. Therefore, effective anti-metastatic therapeutics must be able to inhibit the proliferation and survival of already-disseminated cancer cells, rather than merely attempt to block escape of these cells from primary tumors. Fortunately, SFN not only inhibited migration and invasion, but also impaired the proliferation and survival in U87MG and U373MG cells in a dose-dependent manner. Thus, SFN is just the effective agent we desired.

In conclusion, here we revealed that SFN activated ERK1/2 in a sustained way, further downregulated MMP-2 and upregulated CD44v6, resulting in the inhibition of invasion in glioblastoma cells. Our results may give new insights into the molecular mechanisms of SFN regulation, and provide a potential way to treat glioblastoma.
Author Contributions
Conceived and designed the experiments: CL YZ HT. Analyzed the data: CL LD GY. Contributed reagents/materials/analysis tools: CL YZ XP. Wrote the paper: CL YZ.

References
1. Bai RY, Staerkel V, Giggins GJ (2011) Molecular targeting of glioblastoma: Drug discovery and therapies. Trends Mol Med 17: 301–312.
2. Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011–1018.
3. Stupp R, Rioja F (2009) Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20 Suppl 4: 126–128.
4. Gideon PR, Aliq B, Ma N, Chen VC, Hung X, et al. (2013) Connexin33 confers Temozolomide resistance in human glioma cells by modulating the mitochondrial apoptosis pathway. Neuropharmacology 75: 539–48.
5. Chamberlain MC (2010) Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. Expert Rev Neurother 10: 1537–1544.
6. Higdon JV, Delage B, Williams DE, Dashwood RH (2007) Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res 55: 224–236.
7. Zhang Y, Talalay P, Cho OG, Posner GH (1992) A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci U S A 89: 2399–2403.
8. Tomczyk J, Olejnik A (2010) [Sulforaphane—a possible agent in prevention and therapy of cancer]. Postepy Hig Med Dosw (Online) 64: 590–603.
9. Hahn ER, Chandra-Kundu K, Desai D, Amin S, Singh SV (2012) Notch activation is dispensable for D, L-sulforaphane-mediated inhibition of human prostate cancer cell migration. PLOS ONE 7: e49557.
10. Shan Y, Lao Y, Bao Y, Li B, He C, et al. (2013) Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP-9, S-nitroso-Cys, and mRNAs/ZEB1 pathways in human bladder cancer cells. J Nutr Biochem 24: 1062–1069.
11. Lee HG, Lee KE, Kim JH, Shin HK, Yoon YV (2011) Sulfuric acid inhibits oral carcinoma cell migration and invasion in vitro. Phytother Res 25: 1623–1628.
12. Lee YR, Noh EM, Han JH, Kim JH, Hwang BM, et al. (2013) Sulforaphane controls TPA-induced MMP-9 expression through the NF-kappaB signaling pathway, but not that of NF-kappaB in MCF-7 breast cancer cells. BMC Rep 46: 201–206.
13. Judd NP, Winkler AE, Murillo-Sauca O, Brotman JJ, Law JH, et al. (2012) ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res 72: 363–374.
14. Lau MT, So WK, Leung PC (2013) Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells. PLOS ONE 8: e56983.
15. Thomas SL, Alam R, Lemke N, Schultz LR, Gutierrez JA, et al. (2010) PTEN negatively regulates cAMP response element-binding protein (CREB) activity via a novel MAPK pathway, but not AP-1, in MCF-7 breast cancer cells. BMB Rep 46: 201–206.
16. Marshall CJ (1995) Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 60: 179–185.
17. Liu Z, Yu X, Shaikh ZA (2008) Rapid activation of ERK1/2 and AKT in human breast cancer cells by cadmium. Toxicol Appl Pharmacol 228: 268–294.
18. Xu Y, Zhou J, Wu C, Oser E, Fehahy S, Flaherty CO, Harvey BJ (2006) Estrogen induces phospholipase A2 activation through ERK1/2 to mobilize intracellular calcium in MCF-7 cells. Steroids 71: 256–265.
19. Tong WG, Ding XZ, Talaniotti MS, Bell RH, Adrian TE (2005) LGTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI3-kinase pathways. Biochem Biophys Res Commun 335: 949–956.
20. Chakraborty C, Barbin VP, Chakraborti S, Chidcar P, Dixon SJ, et al. (2003) Endothelin-1 promotes migration and induces elevation of [Ca2+]i and phosphorylation of MAP kinase of a human extravillous trophoblast cell line. J Biol Chem 278: 1893–1903.
21. Shi MD, Shih YW, Lee YS, Chen BC, Tsai LY (2013) Suppression of 12-O-tetradecanoylphorbol-13-acetate-induced MMP-2 breast adenocarcinoma cell invasion/migration by alpha-tomatine through activating PKCalpha/ERK/NF-kappaB-dependent MMP-2/MMP-9 expressions. Cell Biochem Biophys 66: 161–174.
22. Broussard JA, Webb DJ, Kaverina I (2008) Asymmetric focal adhesion disassembly in motile cells. Curr Opin Cell Biol 20: 85–90.
23. Bowden ET, Onokoyi E, Slack R, Myoua A, Youeda T, et al. (2006) Co-localization of cortactin and phosphotyrosine identifies active invasivepoda in human breast cancer cells. Exp Cell Res 312: 1240–1253.
24. Herder KH, Kathan H, Sehle G, Munzer G (2004) CD46uacs: a target for antibody-based cancer therapy. Cancer Immunol Immunother 53: 567–579.
25. Herrlich P, Morrison H, Slcema J, Orian-Rousseau V, Konig H, et al. (2000) CD46 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann N Y Acad Sci 910: 106–118; discussion 118–120.
26. Yang JL, Lin JH, Yuan X, Xiong H, Chen B, Wu JX (2012) PLK1 gene suppresses cell migration and invasion of Hela cancer cells. J Cell Biochem 24: 1062–1069.
27. Zhang XG, Lu XF, Jiao XM, Chen B, Wu JX (2012) PLK1 gene suppresses cell migration and invasion of Hela cancer cells. J Cell Biochem 112: 237–244.
28. Feng W, Liu J, Chen WC, Wang MY, Chen YL, Huang TY (2013) Growth Inhibition and Apoptosis of Neuroblastoma Cells Through ROS-Independent MEK/ERK Activation by Sulforaphane. Cell Biochem Biophys 60(3): 763–74.
29. Teeling K, Li C, Wu W (2013) Human chorionic gonadotropin beta induces cell motility via ERK1/2 and MMP2 activation in human glioblastoma U87MG cells. J Neurooncol 111: 237–244.
30. Roomi MW, Monterrey JC, Kalinovsky T, Rath M, Niedzwiecki A (2009) Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Onco Rep 21: 1233–1333.
31. Rao JS (2003) Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 3: 483–491.
32. Huang TY, Chang WC, Wang MY, Yang YR, Hsu YC (2012) Effect of sulforaphane on growth inhibition in human brain malignant glioma GBM 8401 cells by means of mitochondrial- and MEK/ERK-mediated apoptosis pathway. Cell Biochem Biophys 63: 247–259.
49. Griebling T, Palecek P, Cohen M (1997) Immunohistochemical and soluble expression of CD44 in primary and metastatic human prostate cancers. Int J Oncol 10: 697–702.
50. Elci S, Cerwinka WH, Duncan R, Gomez P, Civantos F, et al. (2004) Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer. Int J Cancer 112: 121–129.
51. Hanlon N, Coldham N, Gielbert A, Kuhnert N, Sauer MJ, et al. (2008) Absolute bioavailability and dose-dependent pharmacokinetic behaviour of dietary doses of the chemopreventive isothiocyanate sulforaphane in rat. Br J Nutr 99: 559–564.
52. Kallifatidis G, Rausch V, Baumann B, Apel A, Beckermann BM, et al. (2009) Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut 58: 949–963.
53. Choi S, Singh SV (2005) Bax and Bak are required for apoptosis induction by sulforaphane, a cruciferous vegetable-derived cancer chemopreventive agent. Cancer Res 65: 2035–2043.